ES2191174T3 - (-)hidroxicitrato de magnesio, procedimiento de preparacion, aplicaciones y composiciones principalmente farmaceuticas que lo contienen. - Google Patents

(-)hidroxicitrato de magnesio, procedimiento de preparacion, aplicaciones y composiciones principalmente farmaceuticas que lo contienen.

Info

Publication number
ES2191174T3
ES2191174T3 ES97911285T ES97911285T ES2191174T3 ES 2191174 T3 ES2191174 T3 ES 2191174T3 ES 97911285 T ES97911285 T ES 97911285T ES 97911285 T ES97911285 T ES 97911285T ES 2191174 T3 ES2191174 T3 ES 2191174T3
Authority
ES
Spain
Prior art keywords
magnesium
hydroxicitrate
applications
pharmaceutical compositions
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97911285T
Other languages
English (en)
Inventor
Ravi Shrivastava
Patrick Lambropoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2191174T3 publication Critical patent/ES2191174T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/02—Magnesium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

EL (-)HIDROXICITRATO DE MAGNESIO, PROCEDIMIENTO DE PREPARACION, APLICACIONES EN DIETETICA Y EN TERAPEUTICA PARTICULARMENTE EN EL CAMPO CARDIOVASCULAR Y COMPOSICIONES PARTICULARMENTE FARMACEUTICAS QUE LO CONTIENEN.
ES97911285T 1996-10-22 1997-10-17 (-)hidroxicitrato de magnesio, procedimiento de preparacion, aplicaciones y composiciones principalmente farmaceuticas que lo contienen. Expired - Lifetime ES2191174T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9613094A FR2754820B1 (fr) 1996-10-22 1996-10-22 Le (-)hydroxycitrate de magnesium, procede de preparation, applications, et compositions notamment pharmaceutiques le renfermant

Publications (1)

Publication Number Publication Date
ES2191174T3 true ES2191174T3 (es) 2003-09-01

Family

ID=9497072

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97911285T Expired - Lifetime ES2191174T3 (es) 1996-10-22 1997-10-17 (-)hidroxicitrato de magnesio, procedimiento de preparacion, aplicaciones y composiciones principalmente farmaceuticas que lo contienen.

Country Status (11)

Country Link
US (1) US6221901B1 (es)
EP (1) EP0937085B1 (es)
JP (1) JP2001503744A (es)
KR (1) KR20000052687A (es)
AT (1) ATE231511T1 (es)
AU (1) AU717533B2 (es)
CA (1) CA2268876A1 (es)
DE (1) DE69718662T2 (es)
ES (1) ES2191174T3 (es)
FR (1) FR2754820B1 (es)
WO (1) WO1998017671A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2733418B1 (fr) * 1995-04-28 1997-08-01 Ravi Shrivastava Nouvelles associations comprenant du (-) hydroxycitrate et presentant notamment de nouvelles activites therapeutiques
US6160172A (en) * 1997-08-27 2000-12-12 Vittal Mallya Scientific Research Foundation Soluble double metal salt of group IA and IIA of (-) hydroxycitric acid, process of preparing the same and its use in beverages and other food products without effecting their flavor and properties
US6503905B1 (en) * 1998-12-29 2003-01-07 Pfizer Inc 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
US7015250B2 (en) * 2000-02-09 2006-03-21 Glykon Technologies Group, Llc Methods and pharmaceutical preparations for normalizing blood pressure with (-)-hydroxycitric acid
US6476071B1 (en) * 2001-05-07 2002-11-05 Dallas L. Clouatre Correcting polymorphic metabolic dysfunction with (−)-hydroxycitric acid
US6482858B1 (en) 2001-06-20 2002-11-19 Dallas L Clouatre (−)-hydroxycitric acid for wound healing and immunomodulation
US6441041B1 (en) 2001-06-20 2002-08-27 Dallas L. Clouatre (-)-hydroxycitric acid for the prevention of osteoporosis
US20030187055A1 (en) * 2002-02-25 2003-10-02 Riker Donald K. Synergistic pharmaceutical combinations for treating obesity
FR2838645B1 (fr) * 2002-04-19 2004-05-28 Ravi Shrivastava Nouvelles compositions synergiques de vitamines, de mineraux et d'oligo-elements pour stimuler l'elimination des lipides intracellulaires
US7507421B2 (en) * 2002-04-30 2009-03-24 Unibar Corporation Hydroxycitric acid salt composition and method of making
US8394856B2 (en) * 2002-07-02 2013-03-12 Glykon Technologies Group, Llc (-)-Hydroxycitric acid for controlling inflammation
US20040049624A1 (en) * 2002-09-06 2004-03-11 Oak Technology, Inc. Network to computer internal interface
US7189416B2 (en) * 2002-11-23 2007-03-13 Glykon Technologies Group, Llc Method for stable and controlled delivery of (-)-hydroxycitric acid
JP3655292B2 (ja) * 2003-04-14 2005-06-02 株式会社日立製作所 粒子線照射装置及び荷電粒子ビーム照射装置の調整方法
AU2003241151A1 (en) * 2003-05-19 2004-12-03 Indfrag Limited A novel composition of complex metal salt of garcinia acid, a process for preparing the same and use thereof
WO2004105733A1 (en) * 2003-05-29 2004-12-09 Glykon Technologies Group, Llc Method and composition for stable and controlled delivery of (-)-hydroxycitric acid
WO2005007088A2 (en) * 2003-07-03 2005-01-27 Unibar Corporation Stabilized anthocyanin extract from garcinia indica
US20050009919A1 (en) * 2003-07-07 2005-01-13 Clouatre Dallas L. Treating cachexia and excessive catabolism with (-)-hydroxycitric acid
JP2007505129A (ja) * 2003-09-11 2007-03-08 グリュコン テクノロジーズ グループ エルエルシー （−）−ヒドロキシクエン酸の腸溶性送達物
KR101100904B1 (ko) * 2003-10-22 2012-01-02 라비 슈리바스타바 세포내 지질 부착물 제거를 자극하는 비타민, 미네랄 및미량원소로 이루어진 새로운 상승작용성 조성물
WO2005085164A1 (en) * 2004-03-09 2005-09-15 Ganga Raju Gokaraju Novel triple mineral salts of (-)-hydroxycitric acid and processes for preparing the same
US7741370B2 (en) * 2004-04-19 2010-06-22 Laila Impex Double salts of (−)-hydroxycitric acid and a process for preparing the same
US20050276839A1 (en) * 2004-06-10 2005-12-15 Rifkin Calman H Appetite satiation and hydration beverage
US20060025483A1 (en) * 2004-07-29 2006-02-02 Clouatre Dallas L (-)-Hydroxycitric acid for protection against soft tissue and arterial calcification
US20060025482A1 (en) * 2004-07-29 2006-02-02 Clouatre Dallas L (-)-Hydroxycitric acid for the modulation of angiotensin-converting enzyme
US20060153934A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and magnesium
WO2019179494A1 (zh) * 2018-03-23 2019-09-26 深圳市塔吉瑞生物医药有限公司 取代的十五烷二酸化合物及药物组合物及其用途
CN109394819A (zh) * 2018-09-14 2019-03-01 中国药科大学 藤黄中一种黄酮类化合物的医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3671583A (en) * 1968-03-25 1972-06-20 Sandoz Ag Glutaric acid derivatives
FR2716374B1 (fr) * 1994-02-18 1996-04-19 Sederma Sa Nouvelles compositions cosmétiques ou dermopharmaceutiques contenant des extraits de plantes.
US5536516A (en) * 1994-08-24 1996-07-16 Renaissance Herbs, Inc. Hydroxycitric acid concentrate and food products prepared therefrom
FR2733418B1 (fr) * 1995-04-28 1997-08-01 Ravi Shrivastava Nouvelles associations comprenant du (-) hydroxycitrate et presentant notamment de nouvelles activites therapeutiques
US5626849A (en) * 1995-06-07 1997-05-06 Reliv International, Inc. Weight loss composition for burning and reducing synthesis of fats

Also Published As

Publication number Publication date
FR2754820A1 (fr) 1998-04-24
KR20000052687A (ko) 2000-08-25
DE69718662D1 (de) 2003-02-27
US6221901B1 (en) 2001-04-24
EP0937085B1 (fr) 2003-01-22
ATE231511T1 (de) 2003-02-15
DE69718662T2 (de) 2003-10-09
WO1998017671A1 (fr) 1998-04-30
EP0937085A1 (fr) 1999-08-25
CA2268876A1 (fr) 1998-04-30
JP2001503744A (ja) 2001-03-21
AU4871797A (en) 1998-05-15
FR2754820B1 (fr) 1999-10-22
AU717533B2 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
ES2191174T3 (es) (-)hidroxicitrato de magnesio, procedimiento de preparacion, aplicaciones y composiciones principalmente farmaceuticas que lo contienen.
PT1036058E (pt) Deribvados de adamantano
AP9801392A0 (en) Concentrated antibody preparation.
ATE224360T1 (de) Adamantan-derivate
DE69905170D1 (en) Thiazolopyrimidinderivate
DE69910230D1 (de) Paclitaxel enthaltende arzneimittel
GR3026758T3 (en) Lactobacillus strains of human origin, their compositions and uses thereof
SE9704546D0 (sv) Novel compounds
IT8821134A0 (it) Frazioni oligomeriche procianidoliche, loro procedimentodi preparazione e composizioni farmaceutiche che le contengono.
NZ333966A (en) Use of 1-nonen-3-one as a flavouring agent
SE9802937D0 (sv) Novel compounds
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
NO964238L (no) Halofantrin-fri-base for behandling av malaria og blandinger
MD970269A (en) Clavulanates
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments
EP0612840A3 (de) Cyclische Verbindungen und ihre Anwendung als Riechstoffe.
ZA961983B (en) Bicyclic compounds, preparation thereof and use in pharmaceutical compositions.
AU6849198A (en) Neurotrypsin
WO1998038994A3 (de) Kombinationspräparat aus 2-methylthiazolidin-2,4-dicarbonsäure und paracetamol
ITMI941696A0 (it) 8-fluoro-antracicline, loro processi di preparazione e composizioni farmaceutiche che le contengono
DE69726602D1 (en) Hepatitis b inhibitoren
AU7655600A (en) 1,4-dioxacycloalkane-2-one and 1,4-dioxacycloalkene-2-one
AU5994696A (en) Modified alpha-d-glcp-(1-2)-alpha-d-glcp-(1-3)-alpha-d-glcp- analogues
UA29496C2 (uk) Ротор для перемішуючих пристроїв
GEU1998374Y (en) Method for Receiving Means for Treatment of Cardiovascular Diseases